论文信息 - Treating and Preventing HIV with Generic Drugs - Barriers in the United States.

Treating and Preventing HIV with Generic Drugs - Barriers in the United States.

Treating and Preventing HIV with Generic Drugs Most of the discussion about the availability of generic HIV drugs focuses on low- and middle-income countries. In the United States, numerous legal, clinical, and market factors create barriers to the adoption of generics as well as uncertainty about cost savings.

B. Schackman | E. Martin | Erika G. Martin | Bruce R. Schackman | Bruce R Schackman

[1] K. Petrie,et al. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review , 2015, BMJ Open.

[2] L. Gerbaud,et al. Perception of Antiretroviral Generic Medicines: One-Day Survey of HIV-Infected Patients and Their Physicians in France , 2015, PloS one.

[3] Richard D Moore,et al. The Lifetime Medical Cost Savings From Preventing HIV in the United States , 2015, Medical care.

[4] M. Weinstein,et al. Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States , 2013, Annals of Internal Medicine.

[5] P. Sax,et al. Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide , 2014, Annals of Internal Medicine.